Cerecor signs deal with Merck for potential CNS drugs

Baltimore-based biotech firm Cerecor secured exclusive global rights to develop and market compounds that inhibit catechol-O-methyltransferase from Merck & Co. Cerecor said the agents have the potential to be used as treatments for addiction, schizophrenia and other central nervous system disorders. Cerecor will review more than 2,000 drug candidates and select some for clinical development. Merck could get milestone fees and sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News · Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC